オプションチェーンは、89bioの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、89bioの市場センチメントを評価します。.

89bio (NASDAQ:ETNB) 株価情報, オプションチェーン

89bio

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

89bio Inc

DA Davidson analyst Brian Holland downgrades Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) from Buy to Neutral and raises the price target from $66 to $68.

News

Downgrades

Price Target

Analyst Ratings

MDLZ

DA Davidson Downgrades Mondelez International to Neutral, Raises Price Target to $68

Marine Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPX#NYSE">MPX</a>) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.08 by 25 percent. This is a 53.85 percent decrease over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $59.00 million which missed the analyst consensus estimate of $65.90 million by 10.47 percent. This is a 14.91 percent decrease over sales of $69.34 million the same period last year.

Earnings

Earnings Misses

Marine Prods Q1 EPS $0.06 Misses $0.08 Estimate, Sales $59.00M Miss $65.90M Estimate

TechnipFMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) reported quarterly earnings of $0.33 per share which missed the analyst consensus estimate of $0.37 by 10.81 percent. This is a 50 percent increase over earnings of $0.22 per share from the same period last year. The company reported quarterly sales of $2.23 billion which missed the analyst consensus estimate of $2.25 billion by 0.71 percent. This is a 9.40 percent increase over sales of $2.04 billion the same period last year.

TechnipFMC Q1 EPS $0.33 Misses $0.37 Estimate, Sales $2.23B Miss $2.25B Estimate

Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) sees Q2 sales of $10.400 billion vs $10.81 billion analyst estimate.

Guidance

Dow Sees Q2 Sales $10.400B vs $10.81B Est

DA Davidson analyst Brian Holland upgrades Utz Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTZ#NYSE">UTZ</a>) from Neutral to Buy and maintains the price target from $16 to $16.

Upgrades

DA Davidson Upgrades Utz Brands to Buy, Maintains Price Target to $16

Gorman-Rupp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRC#NYSE">GRC</a>) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.44 by 4.55 percent. This is a 53.33 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $163.95 million which missed the analyst consensus estimate of $165.02 million by 0.65 percent. This is a 2.94 percent increase over sales of $159.27 million the same period last year.

Earnings Beats

Gorman-Rupp Q1 EPS $0.46 Beats $0.44 Estimate, Sales $163.95M Miss $165.02M Estimate

Darling Ingredients CEO Says 'Despite the broader challenges faced by the biofuel industry during the first quarter of 2025, Darling Ingredients' core business performed well'

Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>) lowers FY2025 GAAP EPS guidance from $8.16-$8.36 to $8.04-$8.24 vs $8.27 analyst estimate..

Dover Lowers FY2025 GAAP EPS Guidance from $8.16-$8.36 to $8.04-$8.24 vs $8.27 Est

Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>) lowers FY2025 Adj EPS guidance from $9.30-$9.50 to $9.20-$9.40 vs $9.25 analyst estimate. Affirms FY2025 sales outlook from $7.90 billion-$8.06 billion to $7.90 billion-$8.06 billion vs $8.01 billion estimate.

Dover Lowers FY2025 Adj EPS Guidance from $9.30-$9.50 to $9.20-$9.40 vs $9.25 Est; Affirms FY2025 Sales Guidance of $7.90B-$8.06B vs $8.01B Est

Darling Ingredients Sees FY25 Core Business Generating ~$950M-$1B EBITDA

Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>) reported quarterly earnings of $2.05 per share which beat the analyst consensus estimate of $1.98 by 3.54 percent. This is a 19.19 percent increase over earnings of $1.72 per share from the same period last year. The company reported quarterly sales of $1.87 billion which missed the analyst consensus estimate of $1.88 billion by 0.67 percent. This is a 0.96 percent decrease over sales of $1.88 billion the same period last year.

Dover Q1 Adj. EPS $2.05 Beats $1.98 Estimate, Sales $1.87B Miss $1.88B Estimate

First Citizens BancShares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) reported quarterly earnings of $37.79 per share which missed the analyst consensus estimate of $37.91 by 0.32 percent. This is a 28.59 percent decrease over earnings of $52.92 per share from the same period last year. The company reported quarterly sales of $2.29 billion which beat the analyst consensus estimate of $2.26 billion by 1.58 percent. This is the same as the same period last year.

FCNCA

First Citizens BancShares Q1 Adj. EPS $37.79 Misses $37.91 Estimate, Sales $2.29B Beat $2.26B Estimate

Darling Ingredients Q1 EPS $(0.16) Misses $0.40 Estimate, Sales $1.38B Miss $1.45B Estimate

HC Wainwright &amp; Co. analyst Kevin Dede reiterates MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) with a Buy and maintains $28 price target.

Reiteration

MARA

HC Wainwright & Co. Reiterates Buy on MARA Holdings, Maintains $28 Price Target

HC Wainwright &amp; Co. analyst Scott Buck reiterates FlexShopper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FPAY#NASDAQ">FPAY</a>) with a Buy and maintains $2.5 price target.

FPAY

HC Wainwright & Co. Reiterates Buy on FlexShopper, Maintains $2.5 Price Target

KDP reaffirmed its fiscal 2025 guidance for constant currency net sales growth in a mid-single-digit range and Adjusted diluted EPS growth in a high-single-digit range.&nbsp;

Keurig Dr Pepper Reiterated FY25 Net Sales Growing In Mid-Single-Digit Range, Adj. EPS Growing In High-Single-Digit Range On Constant Currency Basis

Materialise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTLS#NASDAQ">MTLS</a>) lowers FY2025 sales outlook from $288.17 million-$304.18 million to $283.93 million-$299.71 million vs $278.67 million estimate.

MTLS

Materialise Lowers FY2025 Sales Guidance from $288.17M-$304.18M to $283.93M-$299.71M vs $278.67M Est

Donegal Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGICB#NASDAQ">DGICB</a>) reported quarterly earnings of $0.66 per share which beat the analyst consensus estimate of $0.36 by 83.33 percent. This is a 450 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $245.17 million which missed the analyst consensus estimate of $249.36 million by 1.68 percent. This is a 1.67 percent increase over sales of $241.14 million the same period last year.

DGICB

Donegal Gr Q1 Adj. EPS $0.66 Beats $0.36 Estimate, Sales $245.17M Miss $249.36M Estimate

Donegal Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGICA#NASDAQ">DGICA</a>) reported quarterly earnings of $0.72 per share which beat the analyst consensus estimate of $0.36 by 100 percent. This is a 453.85 percent increase over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $245.17 million which missed the analyst consensus estimate of $249.36 million by 1.68 percent. This is a 1.67 percent increase over sales of $241.14 million the same period last year.

Comments

89bio

89bio (ETNB) オプション

89bio (NASDAQ:ETNB) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル